Integrase inhibitors effective against human T-cell leukemia virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2011-2017

  Seegulam, Muhammad Esa ^a   Ratner, Lee ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE INHIBITOR; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LYMPHOID CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS DNA CELL DNA INTERACTION; VIRUS TRANSMISSION;

CELL LINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INTEGRASE INHIBITORS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; PYRROLIDINONES; VIRUS INTEGRATION;

EID: 79955546176     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01413-10     Document Type: Article

References (24)

1. Albrecht, B., N. D. Collins, G. C. Newbound, L. Ratner, and M. D. Lairmore. 1998. Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. J. Virol. Methods 75:123-140.
2. Brussel, A., and P. Sonigo. 2003. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J. Virol. 77:10119-10124. (Pubitemid 37122094)
3. Delelis, O., K. Carayon, A. Saib, E. Deprez, and J. F. Mouscadet. 2008. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 5:114.
4. Derse, D., S. A. Hill, P. A. Lloyd, H. Chung, and B. A. Morse. 2001. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J. Virol. 75:8461-8468.
5. Engelman, A., K. Mizuuchi, and R. Craigie. 1991. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67:1211-1221. (Pubitemid 121001533)
6. Hare, S., S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
7. Hazuda, D. J., et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650. (Pubitemid 30070911)
8. Igakura, T., et al. 2003. Spread of HTLV-1 between lymphocytes by virusinduced polarization of the cytoskeleton. Science 299:1713-1716. (Pubitemid 36337193)
9. Khabbaz, R. F., et al. 1992. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N. Engl. J. Med. 326:375-380.
10. Leclercq, I., F. Mortreux, A. S. Gabet, C. B. Jonsson, and E. Wattel. 2000. Basis of HTLV type 1 target site selection. AIDS Res. Hum. Retrovir. 16:1653-1659.
11. Lewinski, M. K., et al. 2006. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2:e60.
12. Lin, H. C., M. Hickey, L. Hsu, D. Medina, and A. B. Rabson. 2005. Activation of human T cell leukemia virus type 1 LTR promoter and cellular promoter elements by T cell receptor signaling and HTLV-1 Tax expression. Virology 339:1-11.
13. Markowitz, M., et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
14. Meekings, K. N., J. Leipzig, F. D. Bushman, G. P. Taylor, and C. R. Bangham. 2008. HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog. 4:e1000027.
15. + T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 98:1858-1861.
16. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
17. Proietti, F. A., A. B. Carneiro-Proietti, B. C. Catalan-Soares, and E. L. Murphy. 2005. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 24:6058-6068.
18. Rabaaoui, S., et al. 2008. Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication. Antimicrob. Agents Chemother. 52:3532-3541.
19. Ratner, L., et al. 2009. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One 4:e4420.
20. Rauch, D., et al. 2009. T-cell activation promotes tumorigenesis in inflammation- associated cancer. Retrovirology 6:116.
21. Robek, M. D., F. H. Wong, and L. Ratner. 1998. Human T-cell leukemia virus type 1 pX-I and pX-II open reading frames are dispensable for the immortalization of primary lymphocytes. J. Virol. 72:4458-4462. (Pubitemid 28188757)
22. Schroder, A. R., et al. 2002. HIV-1 integration in the human genome favors active genes and local hot spots. Cell 110:521-529. (Pubitemid 35232295)
23. Serrao, E., S. Odde, K. Ramkumar, and N. Neamati. 2009. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 6:25.
24. Yoder, K. E., and F. D. Bushman. 2000. Repair of gaps in retroviral DNA integration intermediates. J. Virol. 74:11191-11200.